Sustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment-Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection After 96-Week 300 mg ALG-000184, With or Without Entecavir (ETV)

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Sustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment-Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection After 96-Week 300 mg ALG-000184, With or Without Entecavir (ETV)

	AASLD 2025 Nov 7-11 Wash DC Man-Fung Yuen1